China Universal Asset Management Company’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$430K Sell
9,237
-938
-9% -$45K 0.03% 278
2026
Q1
$526K Sell
10,175
-2,168
-18% -$110K 0.04% 252
2025
Q4
$613K Sell
12,343
-1,086
-8% -$52.8K 0.05% 239
2025
Q3
$642K Sell
13,429
-7,816
-37% -$315K 0.05% 220
2025
Q2
$670K Buy
21,245
+1,893
+10% +$60.7K 0.06% 219
2025
Q1
$634K Sell
19,352
-514
-3% -$18.2K 0.06% 224
2024
Q4
$718K Buy
19,866
+9,267
+87% +$326K 0.07% 207
2024
Q3
$330K Buy
10,599
+4,140
+64% +$129K 0.04% 259
2024
Q2
$173K Sell
6,459
-4,031
-38% -$117K 0.02% 258
2024
Q1
$358K Buy
10,490
+4,176
+66% +$124K 0.05% 217
2023
Q4
$183K Buy
6,314
+4,913
+351% +$130K 0.04% 213
2023
Q3
$38.6K Buy
1,401
+687
+96% +$20.9K 0.01% 245
2023
Q2
$21.5K Sell
714
-19
-3% -$665 0.01% 262
2023
Q1
$26.6K Buy
733
+184
+34% +$7.08K 0.01% 193
2022
Q4
$19.6K Buy
549
+48
+10% +$1.67K 0.01% 173
2022
Q3
$17K Buy
+501
New +$16.3K 0.01% 166

Other funds holding SUPN

China Universal Asset Management Company's SUPN Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Supernus Pharmaceuticals (SUPN) stake by 9.2% in Q2 2026, selling an estimated $45K and leaving 9,237 shares worth $430K. The position accounts for 0.03% of the portfolio, ranked #278.

China Universal Asset Management Company first reported a position in SUPN in Q3 2022 and has held it in 16 quarters since. The position peaked at $718K in Q4 2024. 62 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • China Universal Asset Management Company held 9,237 shares of Supernus Pharmaceuticals worth $430K as of Q2 2026.
  • China Universal Asset Management Company sold 938 Supernus Pharmaceuticals shares in Q2 2026, an estimated $45K.
  • Supernus Pharmaceuticals made up 0.03% of China Universal Asset Management Company's portfolio in Q2 2026, its #278 holding.
  • China Universal Asset Management Company first reported a position in Supernus Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Supernus Pharmaceuticals position peaked at $718K in Q4 2024.
  • 62 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.